The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases.
 
Ramya Ramaswami
Research Funding - Celgene (Inst); Genentech (Inst)
 
Kathryn Anne Lurain
Research Funding - Celgene (Inst); EMD Serono (Inst); Genentech (Inst); Merck (Inst)
 
Anaida Widell
Research Funding - Celgene (Inst)
 
Priscila Hermont Goncalves
Consulting or Advisory Role - Regeneron
Research Funding - Syndax
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Xencor
 
Irene Ekwede
Research Funding - Celgene (Inst)
 
William Douglas Figg
Research Funding - Astellas Pharma (Inst); Biocompatibles (Inst); Celgene (Inst); Nerviano Medical Sciences (Inst); NovaRX (Inst); Pfizer (Inst); TRACON Pharma (Inst)
 
Cody J. Peer
No Relationships to Disclose
 
Ralph Mangusan
No Relationships to Disclose
 
Jomy George
Employment - Merck (I)
Stock and Other Ownership Interests - Merck (I)
 
Seth M. Steinberg
No Relationships to Disclose
 
Vikram Khetani
Employment - Bristol-Myers Squibb; Celgene
Stock and Other Ownership Interests - Bristol-Myers Squibb; Celgene
Patents, Royalties, Other Intellectual Property - Celgene Bristol Myers Squibb
 
Denise Whitby
No Relationships to Disclose
 
Thomas S. Uldrick
Research Funding - Bayer (Inst); Celgene (Inst); Merck (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - As an employee of the U.S. Government, I have provisional patent application regarding methods for the treatment of Kaposi’s sarcoma and KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers (Inst)
 
Robert Yarchoan
Research Funding - Celgene (Inst); CTI BioPharma Corp (Inst); Genentech (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Patent related to increase in immune surface markers by pomalidomide, lenalidomide and related drugs in patients with KSHV-associated diseases (Inst); Patent(s) on the treatment of HIV and hepatitis virus with an antiviral drug and a vaccine to prevent resistance (Inst); Patents on the treatment of Kaposi sarcoma with IL-12 (Inst); Various patents including patents on anti-HIV therapies and soluble IL-2 receptor; mostly expired. (Inst); Various patents on vasostatin, KSHV vIL-6, internalization of surface markers, calreticulin, and calreticulin fragments (Inst)